Claire brings to Regulus more than 25 years of experience in clinical and development operations, with experience in these functions accrued at multiple biotech companies including Sanifit Therapeutics, a company focused on the Phase 3 clinical development of SNF472 in chronic kidney disease. Previously she held similar roles at Mirati Therapeutics, Mast Therapeutics, and Cylene Pharmaceuticals. She earned an MBA from Seton Hall University and holds a Ph.D. in organizational management and leadership from Capella University.